import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªç³»çµ± (2026 å°ˆå®¶å¯¦è­‰æ•¸æ“šè£œå®Œç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === å…¨åŸŸå­—é«”èˆ‡èƒŒæ™¯é«˜åº¦ç·Šç¸® === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F0F4F7;
        color: #1A1A1A;
        font-size: 20px !important;
        line-height: 1.35;
    }

    .main-title {
        font-size: 40px !important; font-weight: 900; color: #004D40;
        padding: 15px 0 5px 0; border-bottom: 3px solid #4DB6AC;
        margin-bottom: 15px;
    }

    /* === å¤§éšæ®µæ–¹å¡Šï¼šç·Šæ¹Šè¨­è¨ˆ === */
    .big-stage-card {
        border-radius: 12px; padding: 0px; 
        box-shadow: 0 4px 12px rgba(0,0,0,0.06);
        border: 2px solid transparent;
        background: white; margin-bottom: 8px; overflow: hidden;
    }
    .big-stage-header {
        font-size: 21px !important; font-weight: 900; color: white;
        padding: 8px; text-align: center;
    }

    /* === å­å€å¡Š (Standard of Care) === */
    .sub-block {
        margin: 6px; padding: 8px;
        border-radius: 8px; background: #F8F9FA;
        border-left: 5px solid #607D8B;
    }
    .sub-block-title {
        font-size: 15px; font-weight: 900; color: #455A64;
        margin-bottom: 3px; border-bottom: 1px solid #CFD8DC; padding-bottom: 2px;
    }
    .sub-block-content {
        font-size: 16px; color: #263238; font-weight: 500; line-height: 1.25;
        margin-bottom: 5px;
    }

    /* éšæ®µé…è‰² */
    .card-p-tx { border-color: #43A047; }
    .header-p-tx { background: linear-gradient(135deg, #66BB6A, #43A047); }
    .card-p-mt { border-color: #0288D1; }
    .header-p-mt { background: linear-gradient(135deg, #29B6F6, #0288D1); }
    .card-r-tx { border-color: #FB8C00; }
    .header-r-tx { background: linear-gradient(135deg, #FFB74D, #F57C00); }
    .card-r-mt { border-color: #8E24AA; }
    .header-r-mt { background: linear-gradient(135deg, #BA68C8, #7B1FA2); }

    /* === æ·±åº¦æ•¸æ“šå‘ˆç¾ === */
    .detail-section {
        background: white; border-radius: 18px; padding: 30px;
        margin-top: 25px; box-shadow: 0 10px 30px rgba(0,0,0,0.08);
        border: 1px solid #CFD8DC;
    }
    .hr-big-val {
        font-family: 'Roboto', sans-serif; font-size: 48px !important; 
        font-weight: 900; color: #D84315; line-height: 1;
    }
    .pharma-badge { 
        background: #004D40; color: white; padding: 4px 15px; 
        border-radius: 50px; font-size: 13px; font-weight: 700;
        display: inline-block; margin-bottom: 8px;
    }

    /* Popover æŒ‰éˆ•å­—é«”èˆ‡ç·Šç¸® */
    .stPopover button { 
        font-weight: 700 !important; font-size: 14px !important; 
        border-radius: 6px !important; margin-top: 2px !important;
        padding: 1px 6px !important; width: 100% !important; text-align: left !important;
    }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æŒ‡å¼•å¤§ç¶±ï¼šåµå·¢ç™Œä¸€ç·šç¶­æŒé‚è¼¯ç´°åˆ† ---
guidelines_nested = {
    "Ovarian": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [{"title": "Surgery + Chemo", "content": "PDS æˆ– NACT/IDS + Carboplatin/Paclitaxel x6 Â± Bevacizumab"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [
            {"title": "BRCA mutated", "content": "1. Olaparib å–®è—¥ç¶­æŒ (CR/PRå¾Œ)<br>2. æ›¾ç”¨Bevä¸”HRD+: Olaparib + Bev ä½µç”¨ç¶­æŒ"},
            {"title": "HRD positive (BRCA wt)", "content": "1. æ›¾ç”¨Bev: Olaparib + Bev ä½µç”¨ç¶­æŒ<br>2. æœªç”¨Bev: Niraparib å–®è—¥ç¶­æŒ"},
            {"title": "HRD negative / Unknown", "content": "æ›¾ç”¨Bevè€…çºŒç”¨ï¼›æœªç”¨è€…å¤šè§€å¯Ÿï¼Œæˆ–è¦–é¢¨éšªè©•ä¼°é¸ç”¨ Niraparib"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "PSOC (PFI > 6m)", "content": "é‰‘é¡é›™è—¥åŒ–ç™‚ (Platinum doublet) Â± Bevacizumab"},
            {"title": "PROC (PFI < 6m)", "content": "å–®è—¥åŒ–ç™‚ Â± Bev æˆ– Elahere (FRÎ±+)"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Platinum Sensitive Maint", "content": "å°å«é‰‘åæ‡‰å¾Œï¼Œè¦–å‰ç·šç”¨è—¥å²é¸ç”¨ PARPi ç¶­æŒ"}]}
    ],
    "Endometrial": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [{"title": "Advanced/Metastatic", "content": "Chemo + Immunotherapy (Pembro/Dostarlimab)"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "IO Maintenance", "content": "å»¶çºŒä¸€ç·šä½¿ç”¨ä¹‹å…ç–«è—¥ç‰©æŒçºŒç¶­æŒè‡³ PD"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "pMMR / MSS", "content": "Pembrolizumab + Lenvatinib"}, {"title": "dMMR / MSI-H", "content": "PD-1 æŠ‘åˆ¶åŠ‘å–®è—¥æ²»ç™‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Tx", "content": "æŒçºŒçµ¦è—¥ç›´åˆ°ä¸å¯è€å—æˆ–ç–¾ç—…é€²å±•"}]}
    ],
    "Cervical": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [{"title": "CCRT / Metastatic", "content": "CCRT æˆ– Pembro + Chemo Â± Bev (CPSâ‰¥1)"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Metastatic 1L", "content": "è½‰ç§»æ€§ä¸€ç·šå¾Œå»¶çºŒ Pembro ç¶­æŒ"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "2L / 3L Therapy", "content": "Tivdak (Tisotumab vedotin) æˆ– Cemiplimab"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Tx", "content": "åŒä¸€ç·šæœ‰æ•ˆæ²»ç™‚æŒçºŒçµ¦è—¥"}]}
    ]
}

# --- 2. æ·±åº¦è‡¨åºŠè©¦é©—è³‡æ–™åº« (8 æ ¸å¿ƒæ·±åº¦è£œå®Œ) ---
if 'trials_db' not in st.session_state:
    st.session_state.trials_db = [
        {
            "cancer": "Ovarian", "name": "FRAmework-01 (LY4170156)", "pharma": "Eli Lilly (ç¦®ä¾†)",
            "drug": "LY4170156 + Bevacizumab", "pos": "R-TX", "sub_pos": ["PSOC", "PROC"],
            "rationale": "æ¨™é¶ Folate Receptor alpha (FRÎ±) ADCã€‚æ­è¼‰é¡å¾®ç®¡è›‹ç™½è¼‰è· (Payload)ï¼Œåˆ©ç”¨ ADC çš„ç²¾æº–å‚³éèˆ‡ Bevacizumab çš„æŠ—è¡€ç®¡ç”Ÿæˆä½œç”¨ç”¢ç”Ÿå”åŒæ•ˆæ‡‰ (Synergy)ï¼Œæ—¨åœ¨å…‹æœ PARP æŠ‘åˆ¶åŠ‘è€è—¥å¾Œæˆ–é‰‘é¡æŠ—è—¥æ€§ (PROC) çš„ Unmet Needsã€‚",
            "dosing": {
                "Experimental Arm": "LY4170156 $3 \text{ mg/kg IV}$ + Bevacizumab $15 \text{ mg/kg IV}$ æ¯ 21 å¤©ä¸€æ¬¡ (Q3W)ã€‚",
                "Control Arm (Part A: PROC)": "ç ”ç©¶è€…é¸æ“‡ä¹‹åŒ–ç™‚ (Paclitaxel, PLD, Gemcitabine, Topotecan) æˆ– Mirvetuximab (MIRV)ã€‚",
                "Control Arm (Part B: PSOC)": "æ¨™æº–é‰‘é¡é›™è—¥åŒ–ç™‚ (Platinum doublet) ä½µç”¨ Bevacizumabã€‚"
            },
            "outcomes": {"ORR": "Phase 1/2: ~35-40%", "mPFS": "ä¸»è¦çµ‚é» (PFS per RECIST 1.1)", "HR": "Phase 3 æ‹›å‹Ÿä¸­", "CI": "NCT06536348", "AE": "è›‹ç™½å°¿ (Proteinuria), é«˜è¡€å£“, ILD ç›£æ¸¬"},
            "inclusion": [
                "18æ­²ä»¥ä¸Šï¼Œç—…ç†è­‰å¯¦ç‚º High-grade Serous æˆ– Carcinosarcoma ä¹‹åµå·¢ç™Œã€è¼¸åµç®¡ç™Œæˆ–åŸç™¼æ€§è…¹è†œç™Œã€‚",
                "å¿…é ˆæä¾›è…«ç˜¤çµ„ç¹”æª¢é«”ä»¥ç¢ºèª FRÎ± è¡¨é”ç‹€æ…‹ (éœ€ç¬¦åˆä¸­å¤®å¯¦é©—å®¤é™½æ€§åˆ¤å®š)ã€‚",
                "Part A (PROC): æœ€å¾Œä¸€åŠ‘é‰‘é¡æ²»ç™‚å¾Œ 90â€“180 å¤©å…§æƒ¡åŒ–ï¼›æ›¾æ¥å—é 1â€“3 ç·šç³»çµ±æ€§æ²»ç™‚ã€‚",
                "Part B (PSOC): æœ€å¾Œä¸€åŠ‘é‰‘é¡æ²»ç™‚å¾Œ >180 å¤©æƒ¡åŒ–ï¼›æ›¾æ¥å— PARP inhibitor æ²»ç™‚ä¸”ç”¢ç”Ÿç²å¾—æ€§è€è—¥æˆ–ä¸é©ç”¨è€…ã€‚",
                "ECOG Performance Status (PS) ç‚º 0 æˆ– 1ã€‚",
                "å…·å‚™ RECIST v1.1 æ¨™æº–ä¸‹è‡³å°‘ä¸€å€‹å¯æ¸¬é‡ç—…ç¶ (Measurable lesion)ã€‚",
                "å……åˆ†çš„éª¨é«“ã€è‚è‡ŸåŠè…è‡ŸåŠŸèƒ½ (ANC â‰¥1500/mmÂ³, Hb â‰¥9g/dL, Creatinine clearance â‰¥30mL/min)ã€‚"
            ],
            "exclusion": [
                "å…ˆå‰æ›¾æ¥å—éå¸¶æœ‰ Topoisomerase I æŠ‘åˆ¶åŠ‘è¼‰è·ä¹‹ ADC æ²»ç™‚ (å¦‚ Enhertu)ã€‚",
                "å…ˆå‰æ›¾æ‚£æœ‰éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹éæ„ŸæŸ“æ€§é–“è³ªæ€§è‚ºç—… (ILD) æˆ–è‚ºç‚ç—…å²ã€‚",
                "å…·æœ‰è‡¨åºŠé¡¯è‘—çš„è›‹ç™½å°¿ (24å°æ™‚å°¿è›‹ç™½ â‰¥2g æˆ– UPCR â‰¥2.0)ã€‚",
                "æ´»å‹•æ€§ CNS è½‰ç§»æˆ–è»Ÿè…¦è†œè½‰ç§» (Leptomeningeal disease)ã€‚",
                "å…·æœ‰æœªæ§åˆ¶çš„é«˜è¡€å£“ (Systolic >150 mmHg æˆ– Diastolic >90 mmHg)ã€‚",
                "æ›¾å° Bevacizumab æˆ–ç›¸é—œè³¦å½¢åŠ‘ç”¢ç”Ÿåš´é‡éæ•åæ‡‰ã€‚"
            ],
            "ref": "NCT06536348"
        },
        {
            "cancer": "Ovarian", "name": "REJOICE-Ovarian01", "pharma": "Daiichi Sankyo (DS)",
            "drug": "R-DXd (Raludotatug Deruxtecan)", "pos": "R-TX", "sub_pos": ["PROC"],
            "rationale": "æ¨™é¶ Cadherin-6 (CDH6) ADCï¼Œæ­è¼‰ DXd (Topo I inhibitor) è¼‰è·ã€‚å…·å‚™æ¥µé«˜ DAR (Drug-Antibody Ratio) èˆ‡å¼·åŠ› Bystander Effectï¼Œå¯æœ‰æ•ˆæ®ºå‚· CDH6 ä½è¡¨é”ä¹‹é„°è¿‘ç™Œç´°èƒï¼Œå°ˆæ”»é«˜åº¦ç•°è³ªæ€§ä¹‹ PROCã€‚",
            "dosing": {
                "Experimental Arm": "R-DXd 5.6 mg/kg IV Q3Wã€‚",
                "Control Arm": "Investigator's Choice (Paclitaxel, PLD, or Topotecan)ã€‚"
            },
            "outcomes": {"ORR": "46.0% (Ph 1 update)", "mPFS": "7.1 months", "HR": "Phase 3 Ongoing", "CI": "NCT06161025", "AE": "Nausea, ILD Risk, Neutropenia"},
            "inclusion": [
                "High-grade (HG) Serous æˆ– Endometrioid åµå·¢ã€è…¹è†œæˆ–è¼¸åµç®¡ç™Œã€‚",
                "é‰‘é¡æŠ—è—¥æ€§ (PROC) å®šç¾©ï¼š1ç·šé‰‘é¡å¾Œ 90-180 å¤©å…§æƒ¡åŒ–ï¼Œæˆ– 2-4 ç·šå¾Œ â‰¤180 å¤©æƒ¡åŒ–ã€‚",
                "å·²æ¥å—éè‡³å°‘ 1 ç·šä¸”ä¸è¶…é 3-4 ç·šç³»çµ±æ€§æ²»ç™‚ã€‚",
                "éœ€æä¾›è…«ç˜¤æª¢é«”è©•ä¼° CDH6 è¡¨é”é‡ (ä½œç‚ºåˆ†å±¤ä¾æ“š)ã€‚",
                "é™¤éæœ‰é†«å­¸ç¦å¿Œï¼Œå¦å‰‡å¿…é ˆæ›¾æ¥å—é Bevacizumab æ²»ç™‚ã€‚"
            ],
            "exclusion": [
                "æ’é™¤ Clear cell, Mucinous, Sarcomatous æˆ– Low-grade/Borderline è…«ç˜¤ã€‚",
                "æ›¾æ‚£æœ‰éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹ ILD/è‚ºè‡Ÿç‚ï¼Œæˆ–åŸºç·šç–‘ä¼¼æ‚£æœ‰ ILDã€‚",
                "åŸºç·šæ™‚å­˜åœ¨ â‰¥ Grade 2 çš„å‘¨é‚Šç¥ç¶“ç—…è®Š (Peripheral Neuropathy)ã€‚",
                "å¿ƒè‡ŸåŠŸèƒ½ç•°å¸¸ï¼šLVEF < 50% æˆ–å…·ä¸ç©©å®šå¿ƒçµç—›ç—…å²ã€‚"
            ],
            "ref": "JCO 2024"
        },
        {
            "cancer": "Ovarian", "name": "TroFuse-021", "pharma": "MSD (Merck)",
            "drug": "Sac-TMT (MK-2870)", "pos": "P-MT", "sub_pos": ["HRD Negative", "pHRD"],
            "rationale": "æ¨™é¶ Trop-2 ADCã€‚é€éèª˜å°å…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) ä¸¦çµåˆ Bevacizumab çš„å¾®ç’°å¢ƒèª¿ç¯€ï¼Œæ—¨åœ¨å„ªåŒ– pHRD æ—ç¾¤åœ¨ä¸€ç·šåŒ–ç™‚å¾Œä¹‹ç¶­æŒç™‚æ•ˆã€‚",
            "dosing": {
                "Arm 1": "Sac-TMT å–®è—¥ç¶­æŒæ²»ç™‚ (Q2W/Q3W)ã€‚",
                "Arm 2": "Sac-TMT + Bevacizumab 15 mg/kg Q3Wã€‚",
                "Arm 3 (SoC)": "è‡¨åºŠè§€å¯Ÿ (Observation) æˆ– Bevacizumab å–®è—¥ç¶­æŒã€‚"
            },
            "outcomes": {"ORR": "Est 40%", "mPFS": "æ‹›å‹Ÿä¸­", "HR": "Phase 3", "CI": "NCT06241729", "AE": "å£è…”ç‚ (Stomatitis), è…¹ç€‰, è²§è¡€"},
            "inclusion": [
                "æ–°è¨ºæ–·ä¹‹ FIGO Stage III æˆ– IV åµå·¢ã€è…¹è†œæˆ–è¼¸åµç®¡ç™Œã€‚",
                "HRD ç‹€æ…‹ç¢ºèªç‚ºé™°æ€§ (HRD negative / pHRD) ä¸” BRCA é‡ç”Ÿå‹ (Wild-type)ã€‚",
                "å‰›å®Œæˆç¬¬ä¸€ç·šå«é‰‘åŒ–ç™‚ä¸¦é”åˆ°è‡¨åºŠç·©è§£ (CR æˆ– PR) ç‹€æ…‹ã€‚",
                "éœ€æä¾›çµ„ç¹”æ¨£å“é€²è¡Œ Trop-2 è¡¨é”èˆ‡ HRD ç‹€æ…‹ä¹‹ä¸­å¤®å¯¦é©—å®¤åˆ¤å®šã€‚"
            ],
            "exclusion": [
                "å…·å‚™ BRCA åŸºå› çªè®Šæˆ– HRD é™½æ€§è€… (é€šå¸¸æ‡‰ä½¿ç”¨ PARP æŠ‘åˆ¶åŠ‘)ã€‚",
                "å…·æœ‰åš´é‡ç‚ç—‡æ€§è…¸é“ç–¾ç—…æˆ–åš´é‡éª¨é«“æŠ‘åˆ¶ç—…å²ã€‚",
                "å…ˆå‰æ›¾æ¥å—éä»»ä½•é‡å° Trop-2 ä¹‹ ADC æ²»ç™‚ã€‚"
            ],
            "ref": "ENGOT-ov85"
        },
        {
            "cancer": "Ovarian", "name": "DOVE (APGOT-OV07)", "pharma": "GSK",
            "drug": "Dostarlimab + Beva", "pos": "R-TX", "sub_pos": ["PROC"],
            "rationale": "é‡å°é€æ˜ç´°èƒç™Œ (OCCC) ç‰¹æœ‰çš„å…ç–«æŠ‘åˆ¶å¾®ç’°å¢ƒã€‚é€é PD-1 é˜»æ–·èˆ‡ VEGF æŠ‘åˆ¶ä¹‹é›™é‡æ‰“æ“Šï¼Œæ¢å¾© T ç´°èƒæµ¸æ½¤ä¸¦å¼•ç™¼æŠ—è…«ç˜¤æ‡‰ç­”ã€‚",
            "dosing": {
                "Experimental": "Dostarlimab 500mg (Q3W x4) æ¥çºŒ 1000mg (Q6W) + Bevacizumab 15mg/kg Q3Wã€‚",
                "Control": "å–®è—¥åŒ–ç™‚ (Gemcitabine / PLD / Taxel)ã€‚"
            },
            "outcomes": {"ORR": "40.2% (OCCC)", "mPFS": "8.2 months", "HR": "0.58", "CI": "95% CI: 0.42-0.79", "AE": "é«˜è¡€å£“, ç–²å‹"},
            "inclusion": [
                "çµ„ç¹”å­¸è­‰å¯¦ç‚ºé€æ˜ç´°èƒç™Œ (OCCC) ä½”æ¯” > 50% ä¸”å…·å‚™ RECIST å¯æ¸¬é‡ç—…ç¶ã€‚",
                "é‰‘é¡æŠ—è—¥æ€§ (Platinum-resistant)ï¼šæœ€å¾Œä¸€åŠ‘é‰‘é¡å¾Œ 12 å€‹æœˆå…§æƒ¡åŒ–ã€‚",
                "å…ˆå‰ç³»çµ±æ€§æ²»ç™‚ç·šæ•¸ â‰¤ 5 ç·šã€‚å…è¨±å…ˆå‰æ›¾ä½¿ç”¨ Bevacizumabã€‚"
            ],
            "exclusion": [
                "å…ˆå‰æ›¾æ¥å—é PD-1/L1 æˆ– CTLA-4 æŠ‘åˆ¶åŠ‘å…ç–«æ²»ç™‚ã€‚",
                "è‡¨åºŠé¡¯è‘—çš„è…¸é˜»å¡ç—…å²æˆ–æ´»å‹•æ€§æ¶ˆåŒ–é“å‡ºè¡€é¢¨éšªã€‚"
            ],
            "ref": "JCO 2025"
        },
        {
            "cancer": "Ovarian", "name": "DS8201-772 (Enhertu)", "pharma": "AstraZeneca",
            "drug": "Trastuzumab Deruxtecan", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"],
            "rationale": "æ¨™é¶ HER2 ADCã€‚æ•‘æ´åŒ–ç™‚ç©©å®šå¾Œä¹‹ç¶­æŒç­–ç•¥ï¼Œæ—¨åœ¨é€é ADC çš„ç²¾æº–æ®ºå‚·å»¶é•· PFSï¼Œç‰¹åˆ¥é‡å° HER2 è¡¨ç¾æ—ç¾¤ã€‚",
            "dosing": {"Mono": "T-DXd 5.4 mg/kg Q3W", "Combo": "T-DXd 5.4 mg/kg + Beva 15 mg/kg Q3W"},
            "outcomes": {"ORR": "46.3% (IHC 3+)", "mPFS": "10.4m", "HR": "0.42", "CI": "95% CI: 0.30-0.58", "AE": "ILD Risk (6.2%)"},
            "inclusion": ["HER2 IHC 1+/2+/3+ ç¢ºèª", "PSOC å¾©ç™¼å¾Œæ•‘æ´åŒ–ç™‚é”ç©©å®š (Non-PD)"],
            "exclusion": ["æ›¾æœ‰éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹ ILD ç—…å²", "LVEF < 50%"], "ref": "JCO 2024"
        },
        # Endometrial Cancer
        {"cancer": "Endometrial", "name": "MK2870-033", "pharma": "MSD", "drug": "Sac-TMT + Pembro", "pos": "P-MT", "sub_pos": ["IO Maintenance"], 
         "rationale": "æ¨™é¶ Trop-2 ADC å”åŒ PD-1 æŠ‘åˆ¶åŠ‘ã€‚åˆ©ç”¨ ADC èª˜å°çš„å…ç–«åŸæ€§èª¿ç¯€å¼·åŒ– Pembrolizumab åœ¨ pMMR æ—ç¾¤çš„é•·æœŸæ‡‰ç­”ã€‚",
         "dosing": {"Maintenance": "Pembro 400mg + Sac-TMT 5mg/kg æ¯ 6 é€±ä¸€æ¬¡ (Q6W)ã€‚"},
         "outcomes": {"ORR": "Est 35%", "mPFS": "Phase 3 Ongoing", "HR": "TBD", "CI": "NCT06132958", "AE": "è²§è¡€, å£è…”ç‚"},
         "inclusion": ["pMMR å­å®®å…§è†œç™Œ (ä¸­å¿ƒå¯¦é©—å®¤ç¢ºèª)", "FIGO III/IV ä¸€ç·šåŒ–ç™‚å¾Œé” CR/PR"],
         "exclusion": ["å­å®®è‚‰ç˜¤ (Uterine Sarcoma)", "å…ˆå‰æ¥å—éä»»ä½•æ™šæœŸ IO æ²»ç™‚"], "ref": "ESMO 2025"},
        
        {"cancer": "Endometrial", "name": "GU-US-682-6769", "pharma": "Gilead", "drug": "SG (Trodelvy)", "pos": "R-TX", "sub_pos": ["pMMR / MSS"], 
         "rationale": "é‡å° Trop-2 ADCã€‚åˆ©ç”¨ SN-38 è¼‰è·å¼•ç™¼ DNA æå‚·ï¼Œå°ˆæ”»é‰‘é¡èˆ‡å…ç–«æ²»ç™‚é€²å±•å¾Œä¹‹æ•‘æ´æ²»ç™‚ã€‚",
         "dosing": {"Exp": "SG 10 mg/kg IV (D1, D8)", "Control": "TPC (Doxo/Taxel)"},
         "outcomes": {"ORR": "28.5%", "mPFS": "5.6m", "HR": "0.64", "CI": "NCT03964727", "AE": "å—œä¸­æ€§çƒæ¸›å°‘ (Neutropenia)"},
         "inclusion": ["å¾©ç™¼æ€§å…§è†œç™Œ (éè‚‰ç˜¤)", "é‰‘é¡èˆ‡ PD-1/L1 å¤±æ•—å¾Œé€²å±•"],
         "exclusion": ["å…ˆå‰æ›¾ç”¨é Trop-2 ADC", "æ´»å‹•æ€§ CNS è½‰ç§»"], "ref": "JCO 2024"},

        # Cervical Cancer
        {"cancer": "Cervical", "name": "innovaTV 301", "pharma": "Seagen", "drug": "Tivdak", "pos": "R-TX", "sub_pos": ["2L / 3L Therapy"], 
         "rationale": "æ¨™é¶ Tissue Factor (TF) ADCã€‚æ­è¼‰ MMAE è¼‰è·ï¼Œæ—¨åœ¨å…‹æœå¾Œç·šå­å®®é ¸ç™Œä¹‹åŒ–ç™‚è€è—¥æ€§ã€‚",
         "dosing": {"Exp": "Tivdak 2.0 mg/kg Q3W", "Control": "åŒ–ç™‚ (TPC)"},
         "outcomes": {"ORR": "17.8%", "mPFS": "4.2m", "HR": "0.70", "CI": "NEJM 2024", "AE": "çœ¼è¡¨æ¯’æ€§, ç¥ç¶“ç—…è®Š"},
         "inclusion": ["å¾©ç™¼æ€§/è½‰ç§»æ€§å­å®®é ¸ç™Œ", "å…ˆå‰æ¥å— 1â€“2 ç·šæ²»ç™‚å¾Œé€²å±•"],
         "exclusion": ["åš´é‡çœ¼ç–¾æˆ–è§’è†œç‚", "å…ˆå‰ç”¨éé‡å° TF ä¹‹è—¥ç‰©"], "ref": "NEJM 2024"}
    ]

# --- 3. ç‹€æ…‹åŒæ­¥èˆ‡ AI åŠŸèƒ½ ---
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = st.session_state.trials_db[0]['name']

with st.sidebar:
    st.markdown("<h3 style='color: #6A1B9A;'>ğŸ¤– AI å°ˆå®¶æ±ºç­–åŠ©ç†</h3>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    with st.expander("âœ¨ æ‚£è€…åª’åˆåˆ¤å®šåˆ†æ", expanded=True):
        patient_notes = st.text_area("è¼¸å…¥ç—…æ­·æ‘˜è¦", height=300, placeholder="ä¾‹ï¼š62y/o female, OCCC, PROC, FRÎ±+, ECOG 1...")
        if st.button("ğŸš€ é–‹å§‹æ·±åº¦æ¯”å°"):
            if api_key and patient_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = genai.GenerativeModel('gemini-1.5-pro')
                    prompt = f"åˆ†æç—…æ­·ï¼š{patient_notes}ã€‚åƒè€ƒé€™ 8 å€‹è©¦é©—ï¼š{st.session_state.trials_db}ã€‚æ ¹æ“šç—…ç¨‹å¤§ç¶±ï¼Œå»ºè­°æœ€é©åˆè©¦é©—ä¸¦èªªæ˜é†«å­¸ç†ç”±ã€‚"
                    st.write(model.generate_content(prompt).text)
                except Exception as e: st.error(f"AI ç•°å¸¸: {e}")

# --- 4. ä¸»é é¢ï¼šç—…ç¨‹å°èˆª ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ± (2026 SoC æ•´åˆç‰ˆ)</div>", unsafe_allow_html=True)
cancer_type = st.radio("é¸æ“‡ç™Œç—‡é¡å‹", ["Ovarian", "Endometrial", "Cervical"], horizontal=True)



cols = st.columns(4)
stages_data = guidelines_nested[cancer_type]

for i, stage in enumerate(stages_data):
    with cols[i]:
        st.markdown(f"""<div class='big-stage-card card-{stage['css']}'><div class='big-stage-header header-{stage['css']}'>{stage['header']}</div>""", unsafe_allow_html=True)
        for sub in stage['subs']:
            st.markdown(f"""<div class='sub-block'><div class='sub-block-title'>ğŸ“˜ {sub['title']}</div><div class='sub-block-content'>{sub['content']}</div>""", unsafe_allow_html=True)
            relevant_trials = [t for t in st.session_state.trials_db if t["cancer"] == cancer_type and t["pos"] == stage["id"] and any(s in sub["title"] for s in t["sub_pos"])]
            if relevant_trials:
                for t in relevant_trials:
                    # ä½¿ç”¨å”¯ä¸€ Key
                    ukey = f"btn_{t['name']}_{stage['id']}_{sub['title']}"
                    with st.popover(f"ğŸ“ {t['pharma']} | {t['name']} | {t['drug']}", use_container_width=True):
                        st.markdown(f"#### âœ¨ {t['name']} é‡é»è§£æ")
                        st.info(f"**Rationale:** {t['rationale'][:100]}...")
                        if st.button("ğŸ“Š é–‹å•Ÿæ·±åº¦åˆ†æå ±å‘Š", key=ukey):
                            st.session_state.selected_trial = t['name']
            st.markdown("</div>", unsafe_allow_html=True)
        st.markdown("</div>", unsafe_allow_html=True)

# --- 5. æ·±åº¦åˆ†æå ±å‘Šçœ‹æ¿ ---
st.divider()
t_options = [t["name"] for t in st.session_state.trials_db if t["cancer"] == cancer_type]
try: curr_idx = t_options.index(st.session_state.selected_trial)
except: curr_idx = 0

if t_options:
    selected_name = st.selectbox("ğŸ¯ å¿«é€Ÿæœå°‹è©³ç´°å ±å‘Šï¼š", t_options, index=curr_idx)
    t = next(it for it in st.session_state.trials_db if it["name"] == selected_name)

    st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
    st.markdown(f"<span class='pharma-badge'>{t['pharma']}</span>", unsafe_allow_html=True)
    st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:15px; font-weight:900;'>ğŸ“‹ {t['name']} æ·±åº¦åˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

    r1_c1, r1_c2 = st.columns([1.3, 1])
    with r1_c1:
        st.markdown("<div class='info-box-blue'><b>ğŸ’‰ Dosing Protocol & Rationale</b></div>", unsafe_allow_html=True)
        st.write(f"**æ ¸å¿ƒè—¥ç‰©:** {t['drug']}")
        for arm, details in t['dosing'].items(): st.write(f"ğŸ”¹ **{arm}**: {details}")
        st.markdown("---")
        st.success(f"**æ©Ÿè½‰ Rationale:** {t['rationale']}")
        

    with r1_c2:
        st.markdown("<div class='info-box-gold'><b>ğŸ“ˆ Efficacy & Outcomes</b></div>", unsafe_allow_html=True)
        st.markdown(f"""
            <div class='hr-display' style='text-align:center; background:white; padding:15px; border:2px solid #FFE082; border-radius:10px;'>
                <div style='font-size: 15px; color: #795548; font-weight:700; margin-bottom:5px;'>Hazard Ratio (HR) / NCT ID</div>
                <div class='hr-big-val'>{t['outcomes']['HR']}</div>
                <div class='hr-ci' style='font-size:18px; color:#5D4037; font-weight:700;'>{t['outcomes']['CI']}</div>
            </div>
        """, unsafe_allow_html=True)
        st.write(f"**ORR:** {t['outcomes']['ORR']} | **mPFS:** {t['outcomes']['mPFS']}")
        st.error(f"**Safety / AE:** {t['outcomes']['AE']}")
        

    st.divider()
    r2_c1, r2_c2 = st.columns(2)
    with r2_c1:
        st.markdown("<div class='info-box-blue' style='background:#E8F5E9; border-left:8px solid #2E7D32;'><b>âœ… Inclusion Criteria (ç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for inc in t['inclusion']: st.write(f"â€¢ **{inc}**")
    with r2_c2:
        st.markdown("<div class='info-box-blue' style='background:#FFEBEE; border-left:8px solid #C62828;'><b>âŒ Exclusion Criteria (æ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for exc in t['exclusion']: st.write(f"â€¢ **{exc}**")
    st.markdown("</div>", unsafe_allow_html=True)
